Literature DB >> 25669349

Synthesis, central nervous system activity and structure-activity relationship of N-substituted derivatives of 1-arylimidazolidyn-2-ylideneurea and products of their cyclization.

Elżbieta Szacoń1, Marzena Rządkowska, Agnieszka A Kaczor, Ewa Kędzierska, Antonina Mazur, Sylwia Fidecka, Dariusz Matosiuk.   

Abstract

A series of 20 N-substituted derivatives of 1-arylimidazolidyn-2-ylideneurea and products of their cyclization was designed as compounds having double antinociceptive and serotoninergic activity. Ethyl {[(1-arylimidazolidin-2-ylidene)carbamoyl]amino}acetates were prepared from 1-aryl-4,5-dihydro-1H-imidazol-2-amines and ethyl isocyanatoacetate, and then converted with ammonia solution to 2-{[(1-phenylimidazolidin-2-ylidene)carbamoyl]amino}acetamides. Both series of N-substituted derivatives of 1-arylimidazolidyn-2-ylideneureas were subjected to cyclization to respective imidazo[1,2-a][1,3,5]triazines. Chain and cyclic compounds bearing ester moiety affected spontaneous locomotor activity, body temperature of mice as well as showed antinociceptive and serotoninergic activity. Interestingly, their antinociceptive activity was not reversed by naloxone, thus it is not mediated through the opioid system. Chain and cyclic compounds bearing amide moiety were devoid of central nervous system (CNS) activity which may be attributed to unfavorably low lipophilicity (connected with too high polar surface area and too small molecular volume) and poor blood-brain barrier permeation properties.

Entities:  

Keywords:  1-aryl-4; 5-dihydro-1H-imidazol-2-amines; antinociceptive compounds; central nervous system (CNS) activity; imidazo[1,2-a][1,3,5]triazines

Mesh:

Substances:

Year:  2015        PMID: 25669349     DOI: 10.3109/14756366.2014.965699

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  1 in total

1.  Novel Positive Allosteric Modulators of µ Opioid Receptor-Insight from In Silico and In Vivo Studies.

Authors:  Damian Bartuzi; Ewa Kędzierska; Agnieszka A Kaczor; Helmut Schmidhammer; Dariusz Matosiuk
Journal:  Int J Mol Sci       Date:  2020-11-11       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.